Since the beginning of this year, in order to increase the number of innovative drugs and expand the supply capacity of products and services, many domestic and foreign pharmaceutical companies are frequently launching acquisitions
.
For now, mergers and acquisitions between pharmaceutical companies are still accelerating, and there are two main lines of development, namely acquiring product lines or new markets and responding to pressure from payers
.
On December 1, biotechnology company Rocket Pharmaceuticals, Inc.
announced that it has completed the acquisition of Renovacor, Inc.
, which provides Renovacor's advanced program REN-001, an AAV-based gene therapy for BAG3-associated dilated cardiomyopathy (DCM).
On November 21, Merck and Imago BioSciences announced that the former will acquire the latter through its subsidiary for about $1.
35 billion in cash, or $36 per share, more than
double Imago's closing price of $17.
40 on Friday.
The transaction is expected to close
in the first quarter of 2023.
According to the data, Imago is a clinical-stage biopharmaceutical company that develops new drugs
for the treatment of myeloproliferative tumors and other bone marrow diseases.
The company's lead drug candidate is the oral drug Bomedemstat, an oral lysine-specific demethylase 1 (LSD1) inhibitor
.
On November 15, Roche announced the $2 billion acquisition of Jnana's RAPID platform, which will leverage its RAPID chemical proteomics platform to discover novel small molecule drugs
for cancer, tumor, immune-mediated and neurological diseases.
Roche will provide Jnana with an upfront payment of $50 million
.
The agreement includes multiple recent and future milestone payments valued at more than $2 billion
.
In China, the acquisition of local pharmaceutical companies at the end of the year is also continuing
.
Recently, Aier Eye Department announced that the company plans to acquire part of the equity
of 26 hospitals such as Xi'an Aier and Quanzhou Aier for 900 million yuan.
For this acquisition, the company said that it is to seize the good opportunities for the development of the medical industry and take the lead in the future competition
.
At the same time, based on the basic conditions and development trend of the target hospital, it is conducive to the company to improve the regional market layout, form scale effects, and further accelerate the sinking and service
.
On the evening of November 30, Fosun Pharma also announced that its subsidiary GlandPharma intends to acquire 99.
84% of the equity of Cenexi Group, a French CDMO company, and provide shareholder loans
to it.
For this acquisition, Fosun Pharma said that Cenexi Group's CDMO business model is in line
with GlandPharma's long-term development plan.
It is worth mentioning that in recent years, Fosun Pharma has been frequently initiating acquisitions, and on the evening of July 29 this year, it announced that it intends to invest RMB 402.
486 million to acquire 49% of the equity of
Shanghai Futuo held by Fosun Health Control.
The company intends to contribute RMB 402,486,000 in cash to acquire 49% of the equity of Shanghai Futuo held by Fosun Health Control (corresponding to the registered capital of Shanghai Futuo of RMB 387.
1 million).
.
.
.
.
.
.
In general, through mergers and acquisitions, we can quickly increase the layout of many fields and strengthen the further coverage and extension of enterprise products and businesses, so the industry has been setting off a "wave of acquisitions"
.
However, the industry believes that returning to the long-term development of enterprises, pharmaceutical companies still need to pay attention to innovation and research and development, and constantly improve their "hard power" in order to go further
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
